# OnCo record resectable-pdac (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/resectable-pdac/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "resectable-pdac" ;
  schema:name "Resectable pancreatic ductal adenocarcinoma"@en ;
  schema:alternateName "Resectable pancreatic cancer"@en, "Operable pancreatic cancer"@en, "Early-stage PDAC"@en, "Stage I to II pancreatic adenocarcinoma"@en ;
  schema:description "Resectable pancreatic cancer is the minority of pancreatic cancer that the surgeon can remove with clear margins because it has not wrapped around the main arteries or spread. Treatment is an operation, usually a Whipple procedure, followed by six months of combination chemotherapy, which is what turns surgery alone into a real chance of cure."@en ;
  schema:url <https://onco.cc/cancers/resectable-pdac/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pancreatic_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Pancreatic_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "subtype-page", "gastrointestinal" ;
  onco:related <https://onco.cc/cancers/borderline-resectable-pdac/>, <https://onco.cc/cancers/locally-advanced-pdac/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/brca-palb2-pdac/>, <https://onco.cc/cancers/ipmn-cystic-precursors/>, <https://onco.cc/cancers/ampullary/> ;
  onco:technologies <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/neoantigen-mrna-vaccine/>, <https://onco.cc/technologies/kras-inhibitors/>, <https://onco.cc/technologies/eras-perioperative-nutrition/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:targets <https://onco.cc/targets/kras/>, <https://onco.cc/targets/brca/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/eli-002-7p/> ;
  onco:companies <https://onco.cc/companies/biontech/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/revolution-medicines/>, <https://onco.cc/companies/elicio-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pancreatic-cancer-signalling/>, <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/obstructive-jaundice/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/gbrca-mutation/> ;
  onco:trials <https://onco.cc/trials/prodige-24/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/trials/nct06538857/>, <https://onco.cc/trials/nct04969731/>, <https://onco.cc/trials/amplify-7p/> ;
  onco:people <https://onco.cc/people/thierry-conroy/>, <https://onco.cc/people/marc-besselink/>, <https://onco.cc/people/vinod-balachandran/>, <https://onco.cc/people/jurgen-weitz/>, <https://onco.cc/people/richard-schulick/>, <https://onco.cc/people/eileen-oreilly/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/>, <https://onco.cc/key-papers/paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017/>, <https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/>, <https://onco.cc/key-papers/paper-burris-gemcitabine-pancreatic-jco-1997/> ;
  onco:pipeline <https://onco.cc/trials/nct05968326/>, <https://onco.cc/trials/nct07252232/>, <https://onco.cc/drugs/autogene-cevumeran/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/eli-002-7p/>, <https://onco.cc/trials/amplify-7p/>, <https://onco.cc/trials/nct06538857/>, <https://onco.cc/trials/nct04969731/>, <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/>, <https://onco.cc/ideas/idea-bio2-mrd-triggered-neoantigen-vaccine/>, <https://onco.cc/ideas/idea-bio2-prehabilitation-standard/> ;
  onco:standardOfCare <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/technologies/endoscopic-ultrasound-systems/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/resection-margins/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/prodige-24/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/trials/conko-001/>, <https://onco.cc/trials/espac-4/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/trials/preopanc/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/>, <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/gbrca-mutation/>, <https://onco.cc/technologies/pancreatic-surveillance/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/technologies/ct/> .